Atossa Therapeutics Inc 2026年季度报告

ATOSSA THERAPEUTICS, INC. Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company,or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerginggrowth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Large accelerated filer☐Non-accelerated filer☒Emerging growth company☐ ATOSSA THERAPEUTICS, INC.QUARTERLY REPORTFORM 10-Q TABLE OF CONTENTS PART I.FINANCIAL INFORMATION Item 1.Condensed Consolidated Financial Statements - UnauditedCondensed Consolidated Balance SheetsCondensed Consolidated Statements of OperationsCondensed Consolidated Statements of Stockholders' EquityCondensed Consolidated Statements of Cash FlowsNotes to Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal Proceedings27Item 1A.Risk Factors27Item 2.Unregistered Sales of Equity Securities and Use of Proceeds49Item 3.Defaults Upon Senior Securities49Item 4.Mine Safety Disclosures49Item 5.Other Information49Item 6.Exhibits50Signatures51 ATOSSA THERAPEUTICS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(amounts in thousands, except share and per share data)(Unaudited) ATOSSA THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY(amounts in thousands, except share data)(Unaudited) The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. ATOSSA THERAPEUTICS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(amounts in thousands)(Unaudited) ATOSSA THERAPEUTICS, INC.NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) NOTE 1: NATURE OF OPERATIONS Atossa Therapeutics, Inc. (the Company) was incorporated on April 30, 2009, in the State of Delaware to develop and marketmedical devices, laboratory tests and therapeutics to address breast health conditions. The Company is focused on developingproprietary innovative medicines in areas of significant unmet medical need in oncology, with a focus on breast cancer and otherbreast conditions, as well as other rare diseases. NOTE 2: GOING CONCERN The Company's Condensed Consolidated Financial Statements are prepared under the going concern basis of accounting,which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company hasincurred net losses and negative operating cash flows since inception. For the six months ended June 30, 2026, the Companyrecorded a net loss of $18.1 million and used $19.2 million of cash in operating activities. As of June 30, 2026, the Company had$26.1 million in unrestricted cash and cash equivalents and working capital of $25.6 million. The Company has not yet establishedan ongoing source of revenue sufficient to cover its operating costs and allow it to continue as a going concern. The ability of theCompany to continue as a going concern is dependent on the Company obtaining adequate capital to fund operating losses until itbecomes profitable. These conditions raise substantial doubt as to the Company's ability to continue as a going concern. Theaccompanying Condensed Consolidated Financial Statements do not include any adjustments relating to the recoverability andclassification of recorded asset amounts and classification of liabilities should the Company be unable to continue as a goingconcern. In June 2026, the Company raised $4.0 million in net proceeds through a registered direct offering of shares of common stockand warrants. Refer to Note 9 to these Condensed Consolidated Financial Statements. Although the Company received this infusionof capital, management maintains that in order to alleviate the conditions that raise substantial doubt, the Company will need,among other things, additional capital resources. Management plans to obtain such resources for the Company include obtainingcapital from the sale of its equity securities as well as short-term borrowings from banks, stockholders or other related parties ifneeded. However, management cannot provide any assurance that the Company will be successful in accomplishing any of itsplans. The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plansdescribed in the preceding paragraphs and eventually to secure other sources of financing and attain profitable operations. NOTE 3: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The accompanying Condensed Consolidated Financial Statements have been prepared pursuant to the rules of the Securitiesand Exchange Commission (the SEC) and in accordance with accounting principles generally accepted in the United States(GAAP) for interim